UA influences the progression of breast cancer via the AhR / p27 Kip1 /cyclin E pathway
The FASEB Journal · 2024
DOI: 10.1096/fj.202400938r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Zhiying Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Proliferation, Cyclin E, Cyclin-Dependent Kinase Inhibitor p27. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Discipline Construction Project of Guangdong Medical University, Key Platform of Department of Education of Guangdong Province, Zhanjiang Science and Technology Development Special Funding Competitive Allocation Project.
Abstract (Originalsprache)
Uric acid (UA) is the end product of purine metabolism. In recent years, UA has been found to be associated with the prognosis of clinical cancer patients. However, the intricate mechanisms by which UA affects the development and prognosis of tumor patients has not been well elucidated. In this study, we explored the role of UA in breast cancer, scrutinizing its impact on breast cancer cell function by treating two types of breast cancer cell lines with UA. The role of UA in the cell cycle and proliferation of tumors and the underlying mechanisms were further investigated. We found that the antioxidant effect of UA facilitated the scavenging of reactive oxygen species (ROS) in breast cancer, thereby reducing aryl hydrocarbon receptor (AhR) expression and affecting the breast cancer cell cycle, driving the proliferation of breast cancer cells through the AhR/p27 Kip1 /cyclin E1 pathway. Moreover, in breast cancer patients, the expression of AhR and its downstream genes may be closely associated with cancer progression in patients. Therefore, an increase in UA could promote the proliferation of breast cancer cells through the AhR/p27 Kip1 /cyclin E1 pathway axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
- Department of Breast Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
- Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong Province and Macao Regi…
ORCID-Profile: Zhiying Wang, Yuanqi Zhang, Shengchao Huang, Zhihong Liao, Mingzhang Huang, Wei Lei, Xiaorong Shui
Förderung
- Discipline Construction Project of Guangdong Medical University
- Key Platform of Department of Education of Guangdong Province
- Zhanjiang Science and Technology Development Special Funding Competitive Allocation Project
Zitieren
APA
Wang, Z., Zhang, Y., Huang, S., Liao, Z., Huang, M., Lei, W., & Shui, X. (2024). UA influences the progression of breast cancer via the AhR / p27 Kip1 /cyclin E pathway. The FASEB Journal. https://doi.org/10.1096/fj.202400938r
Vancouver
Wang Z, Zhang Y, Huang S, Liao Z, Huang M, Lei W, et al. UA influences the progression of breast cancer via the AhR / p27 Kip1 /cyclin E pathway. The FASEB Journal. 2024. doi:10.1096/fj.202400938r
BibTeX
@article{Wang2024,
author = {Wang, Zhiying and Zhang, Yuanqi and Huang, Shengchao and Liao, Zhihong and Huang, Mingzhang and Lei, Wei and Shui, Xiaorong},
title = {UA influences the progression of breast cancer via the AhR / p27 Kip1 /cyclin E pathway},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202400938r}
}
EUVIMED